



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
College Park, MD 20740

MAY 16 2007

Mr. Don McFarland
President
McLind Corporation
PO Box 3669
Torrance, California 90510-3669

Dear Mr. McFarland:

This is in response to your letter of April 12, 2007 to the Food and Drug Administration (FDA) pursuant to 21 U.S.C. 343(r)(6) (section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act (the Act)). Your submission states that McLind Corporation is making the following claims, among others, for the product Lindberg Inflatrol:

“Excessive, chronic inflammation in the body may lead to deleterious effects, including chronic disease. Diet...determine disease development and progression.”
“Inflatrol...may help support a healthy inflammation response.”

21 U.S.C. 343(r)(6) makes clear that a statement included in labeling under the authority of that section may not claim to diagnose, mitigate, treat, cure, or prevent a specific disease or class of diseases. The statements that you are making for this product suggest that it is intended to treat, prevent, or mitigate diseases. These claims do not meet the requirements of 21 U.S.C. 343(r)(6). These claims suggest that this product is intended for use as a drug within the meaning of 21 U.S.C. 321(g)(1)(B), and that it is subject to regulation under the drug provisions of the Act. If your client intends to make claims of this nature, they should contact FDA's Center for Drug Evaluation and Research (CDER), Office of Compliance, HFD-310, Montrose Metro II, 11919 Rockville Pike, Rockville, Maryland 20852.

2073 7 MAY 23 02 PM '07

1997S-0163

LET 942

Page 2 - Mr. Don McFarland

Please contact us if we may be of further assistance.

Sincerely yours,



Vasilios H. Frankos, Ph.D.
Director
Division of Dietary Supplement Programs
Office of Nutrition, Labeling
and Dietary Supplements
Center for Food Safety
and Applied Nutrition

Copies:

FDA, Center for Drug Evaluation and Research, Office of Compliance, HFD-310

FDA, Office of the Associate Commissioner for Regulatory Affairs, Office of
Enforcement, HFC-200

FDA, San Francisco District Office, Office of Compliance, HFR-PA140


McLind Corporation

Mailing Address: P.O. Box 3669, Torrance, CA 90510-3669
Business Address: 2575 West 237th Street, Torrance, CA 90505

Business: (310) 784-8500
Fax: (310) 784-8528

April 12, 2007

Office of Nutritional Products, Labeling and Dietary Supplements (HFS-810)
Center for Food Safety and Applied Nutrition
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740



Re: Dietary Supplement Statement of Support Notification

To Whom It May Concern:


McLind Corporation, P.O. Box 3669 Torrance, CA 90510-3896, who is the distributor of the following dietary supplement product, intends to make the following statement(s) of support:

"Promotes a Healthy Inflammation Response."

"Excessive, chronic inflammation in the body may lead to deleterious effects, including chronic disease. Diet, exercise, lifestyle and genetics determine disease development and progression. A healthy diet and exercise are two factors within our control to manage this process. Inflatrol combines natural plant ingredients which host phytonutrients that may help support a healthy inflammation response. Turmeric contains a polyphenolic pigment called curcumin, which has been shown to have antioxidant activity as well as other beneficial properties to support cellular health. Bromelain (from pineapple) and papain (from papaya) are two plant enzymes with proteolytic activity. Quercetin is a naturally occurring bioflavonoid shown to promote vascular health. Green tea is a powerful antioxidant due mostly to its high polyphenol (especially EGCG) content."

These claims are being made for a product named Lindberg® Inflatrol. This submission is being made in compliance with 21 CFR §101.93.

The undersigned is an authorized representative of the McLind Corporation and certifies that the information contained in this notice is complete and accurate, and that McLind Corporation has substantiation that the above statement(s) is (are) truthful and not misleading.

By: 
Don McFarland
President

2007-2709

1911